<DOC>
	<DOCNO>NCT01886287</DOCNO>
	<brief_summary>The primary purpose study investigate effect high-dose octreotide flush , diarrhea , quality life patient whose disease-related symptom inadequately control maximum approve dose octreotide LAR .</brief_summary>
	<brief_title>P : II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome</brief_title>
	<detailed_description>The study population consist patient advance ( metastatic unresectable ) neuroendocrine tumor suboptimally control carcinoid syndrome . While majority patient primary tumor ileocecum ( midgut ) , serotonin-producing neuroendocrine tumor eligible ( include pancreatic , lung unknown primary ) . All patient follow adverse event serious adverse event 28 day follow last dose above-label octreotide , resolution stabilization event , whichever come first .</detailed_description>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Metastatic neuroendocrine tumor consider well moderately differentiate ( low intermediate grade ) . Patients poorly differentiate neuroendocrine carcinoma small cell carcinoma exclude study . Elevated urine 5hydroxyindoleacetic acid ( 5HIAA ) More 2 bowelmovements per day OR 4 flush episode per week average Patient currently octreotide LAR 30mg every 3 4 week ( least 3 cycle prior screen ) Age ≥ 18 year Minimum four week since major surgery , liverdirected therapy ( embolization , etc . ) systemic cancer treatment octreotide LAR Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Life expectancy &gt; 12 week Reliable contraception maintain throughout study 3 month study drug discontinuation . Signed informed consent participate study must obtain patient fully inform nature potential risk investigator ( his/her designee ) aid write information . Known hypersensitivity somatostatin analogues Patients poorly differentiate neuroendocrine cancer Patients liver cirrhosis Patients receive hemodialysis peritoneal dialysis Patients cachexia , opinion investigator , may difficulty tolerate intramuscular injection Patients symptomatic cholelithiasis biliary event within past five year ( undergone cholecystectomy ) Patients recent history ( within 5 year ) pancreatitis Patients uncontrolled diabetes ( HgA1c &gt; 8.0 despite adequate therapy ) Women childbearing potential , UNLESS use two birth control method Women pregnant lactate HIV positive patient History sustain ventricular tachycardia , ventricular fibrillation , advanced heart block , idiopathic syncope think related ventricular arrhythmia , congenital long QT syndrome Risk factor Torsades de Pointes cardiac failure , clinically significant/symptomatic bradycardia Patients severe and/or uncontrolled medical condition condition could affect participation study History noncompliance medical regimen unwillingness comply protocol Patients unable tolerate benefit abovelabel dose octreotide ( &gt; 30mg ) past Concomitant use cancer treatment carcinoid syndrome treatment ( whether standard experimental ) . Patients discontinue concomitant cancer medication two week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>endocrine system</keyword>
	<keyword>neuroendocrine tumor</keyword>
	<keyword>neuroendocrine cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>gastrointestinal ( GI )</keyword>
	<keyword>high-dose octreotide</keyword>
	<keyword>flush</keyword>
	<keyword>diarrhea</keyword>
	<keyword>quality life patient</keyword>
	<keyword>disease-related symptom</keyword>
</DOC>